Appendix C: Standardized Selection Criteria
- Represents a health care drug, intervention, device, or technology available (or soon to be available) in the United States.
- Relevant to Medicare, Medicaid, SCHIP, or other Federal health care programs.
- Represents one of the priority conditions designated by the Department of Health and Human Services.
- Represents a significant disease burden; for a large proportion of the U.S, population or for a priority population in particular.
- Is of high public interest; affects health care decisionmaking, outcomes, or costs for a large proportion of the U.S. population or for a priority population in particular.
- Was nominated/strongly supported by one or more stakeholder groups.
- Represents important uncertainty for decisionmakers.
- Incorporates issues around both benefits and potential harms.
- Represents important variation in clinical care, or controversy in what constitutes appropriate clinical care.
- Represents high costs due to common use, to high unit costs, or to high associated costs to consumers, to patients, to health care systems, or to payers.
C. Feasibility/Desirability of New Research
- Effectively utilizes existing research and knowledge by considering—
- Adequacy (type and volume) of research for conducting a systematic review.
- Newly available evidence (particularly for updates or new technologies).
- Would not be redundant; (i.e., the proposed topic is not already covered by available or soon-to-be available high-quality systematic review by AHRQ or others.)
D. Potential Value
- Potential for significant health impact:
- To improve health outcomes.
- To reduce significant variation in clinical practices known to be related to quality.
- To reduce unnecessary burden on those with health care problems.
- Potential for significant economic impact: to reduce unnecessary or excessive costs.
- Potential for change:
- The proposed topic exists within a clinical, consumer, or policymaking context that is amenable to evidence-based change.
- A product from the EHC program could be an appropriate vehicle.
- Potential risk from inaction: unintended harms from lack of prioritization of a nominated topic.
- Addresses inequities, vulnerable populations (including issues for patient subgroups).
- Addresses a topic that has clear implications for resolving important dilemmas in health and health care decisions made by one or more stakeholder groups.
Return to Contents
Proceed to Next Section